Clinical and immunological characteristics of Autoimmune Addison's disease: a nationwide Swedish multicenter study.
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Context: Studies of the clinical and immunological features of autoimmune Addison disease (AAD) are needed to understand the disease burden and increased mortality. Objective: To provide upgraded data on autoimmune comorbidities, replacement therapy, autoantibody profiles, and cardiovascular risk factors. Design, Setting, and Participants: A cross-sectional, population-based study that included 660 AAD patients from the Swedish Addison Registry (2008-2014). When analyzing the cardiovascular risk factors, 3594 individuals from the population-based survey in Northern Sweden, MONICA (monitoring of trends and determinants of cardiovascular disease), served as controls. Main Outcome Measures: The endpoints were the prevalence of autoimmune comorbidities and cardiovascular risk factors. Autoantibodies against 13 autoantigens were determined. Results: The proportion of 21-hydroxylase autoantibody-positive patients was 83%, and 62% of patients had ≥1 associated autoimmune diseases, more frequently coexisting in females (P < 0.0001). AAD patients had a lower body mass index (P < 0.0001) and prevalence of hypertension (P = 0.027) compared with controls. Conventional hydrocortisone tablets were used by 89% of the patients, with a mean dose of 28.1 ± 8.5 mg/d. The mean hydrocortisone equivalent dose normalized to the body surface was 14.8 ± 4.4 mg/m2/d. A greater hydrocortisone equivalent dose was associated with a greater incidence of hypertension (P = 0.046). Conclusions: Careful monitoring of AAD patients is warranted to detect associated autoimmune diseases. Contemporary Swedish AAD patients did not have an increased prevalence of overweight, hypertension, type 2 diabetes mellitus, or hyperlipidemia. However, high glucocorticoid replacement doses could be a risk factor for hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gale, E. A. M., & Gillespie, K. M. (2001) · Diabetologia · doi:10.1007/s001250051573 · Cited by 558
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 12×
“We have previously shown very high validity for self-reported usage of lipid-lowering drugs within the Northern Sweden MONICA cohort (42).”
BackgroundInfluentialSelf-citationErichsen, M. M., Løvås, K., Skinningsrud, B., Wolff, A. B., Undlien, D. E., Svartberg, J., Fougner, K. J., Berg, T. J., Bollerslev, J., Mella, B., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1368 · Cited by 422
21-hydroxylase, a major autoantigen in idiopathic Addison's disease
Winqvist, O., Karlsson, F. A., & Kämpe, O. (1992) · The Lancet · doi:10.1016/0140-6736(92)91829-w · Cited by 410
Self-citationHusebye, E. S., Allolio, B., Arlt, W., Badenhoop, K., Bensing, S., Betterle, C., Falorni, A., Gan, E. H., Hulting, A. ‐., Kasperlik‐Zaluska, A., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12162 · Cited by 403 · cited 6×
“No difference was found in the hydrocortisone equivalent dose between the 382 Dalin et al Autoimmune Addison Disease in Sweden J Clin Endocrinol Metab, February 2017, 102(2):379–389”
BackgroundMethodInfluentialSelf-citationFilipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 1×
“with secondary adrenal insufficiency have shown that hydrocortisone doses $20 mg are associated with an increase in cardiovascular risk factors (37, 38).”
BackgroundSelf-citationAddison's disease: a survey on 633 patients in Padova
Betterle, C., Scarpa, R., Garelli, S., Morlin, L., Lazzarotto, F., Presotto, F., Coco, G., Masiero, S., Parolo, A., Albergoni, M. P., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0528 · Cited by 90 · cited 6×
“Our female patient group was more prone to autoimmune comorbidity than were the males with AAD, in agreement with general population data and the 2 previous largest cohort studies of primary adrenal insufficiency from Norway and Italy (21, 22).”
BackgroundResultInfluentialGiordano, R., Marzotti, S., Balbo, M., Romagnoli, S., Marinazzo, E., Berardelli, R., Migliaretti, G., Benso, A., Falorni, A., Ghigo, E., et al. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345773 · Cited by 84
Danilowicz, K., Bruno, O. D., Manavela, M., Gomez, R. M., & Barkan, A. (2008) · Pituitary · doi:10.1007/s11102-008-0126-2 · Cited by 72
Björnsdottir, S., Sundström, A., Ludvigsson, J. F., Blomqvist, P., Kämpe, O., & Bensing, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3561 · Cited by 70 · cited 13×
“We have previously shown very high validity for self-reported usage of lipid-lowering drugs within the Northern Sweden MONICA cohort (42).”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Autoimmune Polyendocrine Syndromes
Husebye, E. S., Anderson, M. S., & Kämpe, O. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1713301 · Cited by 466
Self-citationHusebye, E. S., Pearce, S. H., Krone, N. P., & Kämpe, O. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00136-7 · Cited by 378
Self-citationImmune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis
Grouthier, V., Lebrun-Vignes, B., Moey, M., Johnson, D. B., Moslehi, J. J., Salem, J.-E., & Bachelot, A. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0555 · Cited by 126
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency
Arlt, W., Baldeweg, S. E., Pearce, S. H. S., & Simpson, H. L. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0361 · Cited by 107
Increased mortality risk in patients with primary and secondary adrenal insufficiency
Ngaosuwan, K., Johnston, D. G., Godsland, I. F., Cox, J., Majeed, A., Quint, J. K., Oliver, N., & Robinson, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab096 · Cited by 77
Pofi, R., Prete, A., Thornton-Jones, V., Bryce, J., Ali, S. R., Faisal Ahmed, S., Balsamo, A., Baronio, F., Cannuccia, A., Guven, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz055 · Cited by 53
X-linked adrenoleukodystrophy and primary adrenal insufficiency
Cappa, M., Todisco, T., & Bizzarri, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1309053 · Cited by 28
“This condition can occur at any age, with most individuals affected between the age of 20 and 50 (4).”
BackgroundChantzichristos, D., Eliasson, B., & Johannsson, G. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0052 · Cited by 21
Self-citationChantzichristos, D., Persson, A., Miftaraj, M., Eliasson, B., Svensson, A.-M., & Johannsson, G. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02064 · Cited by 9
Self-citation
Metadata
- Authors
- Dalin, F., Nordling Eriksson, G., Dahlqvist, P., Hallgren, Å., Wahlberg, J., Ekwall, O., Söderberg, S., Rönnelid, J., Olcén, P., Winqvist, O., Catrina, S.-B., Kriström, B., Laudius, M., Isaksson, M., Halldin Stenlid, M., Gustafsson, J., Gebre-Medhin, G., Björnsdottir, S., Janson, A., Åkerman, A.-K., Åman, J., Duchen, K., Bergthorsdottir, R., Johannsson, G., Lindskog, E., Landin-Olsson, M., Elfving, M., Waldenström, E., Hulting, A.-L., Kämpe, O., & Bensing, S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-11-21
- Volume
- 102
- Issue
- 2
- Pages
- jc.2016-2522
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2553015755
- Cited by
- 82
- References
- 11
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.